Overview

A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

Status:
Not yet recruiting
Trial end date:
2023-08-27
Target enrollment:
Participant gender:
Summary
This study is designed to assess the effect of BMS-986196 on the drug levels of caffeine, montelukast, flurbiprofen, omeprazole, midazolam, digoxin, and pravastatin in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Caffeine
Digoxin
Flurbiprofen
Midazolam
Montelukast
Omeprazole
Pravastatin